



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application	) PATENT APPLICATION	
Inventor(s): Sudeepta Aggarwal	)	
Application No.: 10/533,069	) Art Unit: 1647 )	
Filed: January 3, 2007	) Examiner: Allen, Marianne )	
Title: Compositions and methods for the treatment of immune related diseases	·	

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

**MAIL STOP: AF** 

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and foreign patent, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. Each of these references listed on the attached form PTO-1449 was cited from the related <u>JP 2004-548574 on 02/05/2010</u>.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			subsection (b) because (check all that apply):
		(1)	It is being filed within 3 months prosecution application under §	of the application filing date and is other than a continued 1.53(d)
		(2)	It is being filed within 3 months OR	of entry of a national stage
		(3)		date of the first Office Action on the merits
		(4)		ng of a first Office Action after the filing of a request for 1.114.
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing do of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:			
		a certif	ication as specified in §1.97(e) is	provided below; or
		a fee of	f \$180.00 as set forth in §1.17(p) nt of other papers filed together w	is authorized below, enclosed, or included with the rith this statement.
$\boxtimes$	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:			ed after the mailing date of the earlier of a final office ler §1.311, but before payment of the issue fee, then:
	A.	a certif	ication as specified in §1.97(e) is	completed below; and
	B.	a petition herewit	on under 37 C.F.R. §1.97(d) requ th; <b>and</b>	esting consideration of this statement is submitted
	C.	a fee of	f \$130.00 as set forth in \$1.17(i)(int of other papers filed together w	) is authorized below, enclosed, or included with the ith this statement.
oxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of and charge any additional fees or credit any overpayment associated with this communication to Dep Account No. 50-2387 (Docket No. GNE-0269 R1 (24126.156)).		payment associated with this communication to Deposit	
				Respectfully submitted, Arnold & Porter LLP
Dated:	O	4 /28	128/0	By Christopher De Vry, Reg. No. 61,425
	& Porte	r LLP eet, NW	,	

Arnold & Porter LLP 555 Twelfth Street, NW Washington, DC 20004-1206 Tel (415) 356-3000 Fax (415) 356-3099 Customer No. 35489